JP2018535663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535663A5 JP2018535663A5 JP2018517380A JP2018517380A JP2018535663A5 JP 2018535663 A5 JP2018535663 A5 JP 2018535663A5 JP 2018517380 A JP2018517380 A JP 2018517380A JP 2018517380 A JP2018517380 A JP 2018517380A JP 2018535663 A5 JP2018535663 A5 JP 2018535663A5
- Authority
- JP
- Japan
- Prior art keywords
- trc1
- seq
- cells
- shows
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237394P | 2015-10-05 | 2015-10-05 | |
| US62/237,394 | 2015-10-05 | ||
| US201662297426P | 2016-02-19 | 2016-02-19 | |
| US62/297,426 | 2016-02-19 | ||
| PCT/US2016/055492 WO2017062451A1 (en) | 2015-10-05 | 2016-10-05 | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213180A Division JP2021072785A (ja) | 2015-10-05 | 2020-12-23 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535663A JP2018535663A (ja) | 2018-12-06 |
| JP2018535663A5 true JP2018535663A5 (https=) | 2020-12-24 |
| JP6816133B2 JP6816133B2 (ja) | 2021-01-20 |
Family
ID=57145061
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517380A Active JP6816133B2 (ja) | 2015-10-05 | 2016-10-05 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| JP2020213180A Pending JP2021072785A (ja) | 2015-10-05 | 2020-12-23 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| JP2022136683A Pending JP2022180388A (ja) | 2015-10-05 | 2022-08-30 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| JP2023074010A Pending JP2023106422A (ja) | 2015-10-05 | 2023-04-28 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| JP2023222699A Pending JP2024045153A (ja) | 2015-10-05 | 2023-12-28 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| JP2025133019A Pending JP2025179069A (ja) | 2015-10-05 | 2025-08-08 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213180A Pending JP2021072785A (ja) | 2015-10-05 | 2020-12-23 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| JP2022136683A Pending JP2022180388A (ja) | 2015-10-05 | 2022-08-30 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| JP2023074010A Pending JP2023106422A (ja) | 2015-10-05 | 2023-04-28 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| JP2023222699A Pending JP2024045153A (ja) | 2015-10-05 | 2023-12-28 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| JP2025133019A Pending JP2025179069A (ja) | 2015-10-05 | 2025-08-08 | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (14) | US9889160B2 (https=) |
| EP (3) | EP3756682B8 (https=) |
| JP (6) | JP6816133B2 (https=) |
| KR (2) | KR20180054886A (https=) |
| CN (2) | CN117070468A (https=) |
| AU (3) | AU2016333898B2 (https=) |
| CA (1) | CA3001011A1 (https=) |
| DK (2) | DK3359184T3 (https=) |
| ES (2) | ES2920525T3 (https=) |
| IL (5) | IL321898A (https=) |
| MX (2) | MX2018004146A (https=) |
| WO (1) | WO2017062451A1 (https=) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| EP3322297B1 (en) * | 2015-07-13 | 2024-12-04 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| EP3359660B1 (en) | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| CN117070468A (zh) * | 2015-10-05 | 2023-11-17 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP6928604B2 (ja) * | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| KR102438360B1 (ko) * | 2016-03-04 | 2022-08-31 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분 |
| CN109415687A (zh) * | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US11377637B2 (en) | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| NZ750256A (en) | 2016-08-03 | 2026-02-27 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| EP3529265A2 (en) * | 2016-10-19 | 2019-08-28 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| EP3612205B9 (en) * | 2017-04-21 | 2023-10-04 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the pcsk9 gene |
| WO2018201144A1 (en) | 2017-04-28 | 2018-11-01 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| EP4029943A1 (en) * | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CA3067382A1 (en) | 2017-06-15 | 2018-12-20 | The Regents Of The University Of California | Targeted non-viral dna insertions |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| US20200270574A1 (en) * | 2017-09-29 | 2020-08-27 | Nantcell, Inc. | CD1d and TCR-NKT Cells |
| BR112020006643A2 (pt) | 2017-10-03 | 2020-09-24 | Juno Therapeutics Inc | moléculas de ligação específica ao hpv |
| CN109628493B (zh) * | 2017-10-09 | 2021-12-07 | 广东赤萌医疗科技有限公司 | 一种用于制备可异体移植t细胞的基因编辑系统 |
| KR102503130B1 (ko) * | 2017-10-27 | 2023-02-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
| MX2020004541A (es) * | 2017-10-30 | 2021-04-12 | Pact Pharma Inc | Edicion de genes de celulas primarias. |
| WO2019106163A1 (en) | 2017-12-01 | 2019-06-06 | Cellectis | Reprogramming of genetically engineered primary immune cells |
| WO2019118508A1 (en) * | 2017-12-12 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting ny-eso-1 and methods of use thereof |
| KR102752985B1 (ko) | 2017-12-20 | 2025-01-10 | 포세이다 테라퓨틱스, 인크. | Vcar 조성물 및 사용 방법 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CA3090791A1 (en) | 2018-02-11 | 2019-08-15 | Memorial Sloan-Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| SG11202009761YA (en) | 2018-04-02 | 2020-10-29 | Pact Pharma Inc | Peptide-mhc compacts |
| KR20210020873A (ko) * | 2018-04-05 | 2021-02-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법 |
| CA3094468A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| CA3096202A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
| CA3095757A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating glioblastomas |
| CA3095795A1 (en) * | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
| US12227763B2 (en) | 2018-05-11 | 2025-02-18 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN113226475B (zh) * | 2018-12-26 | 2026-03-17 | 麒麟控股株式会社 | 改造tcr及其制造方法 |
| IL316576A (en) | 2019-02-12 | 2024-12-01 | Pact Pharma Inc | Preparations and methods for identifying antigen-specific T cells |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US11059864B2 (en) | 2019-03-29 | 2021-07-13 | Trustees Of Boston University | Chimeric antigen receptor (CAR) modulation |
| JP7286796B2 (ja) | 2019-04-03 | 2023-06-05 | プレシジョン バイオサイエンシズ，インク． | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
| AU2020271523A1 (en) * | 2019-04-11 | 2021-10-14 | Fate Therapeutics, Inc. | CD3 reconstitution in engineered iPSC and immune effector cells |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| CA3137975A1 (en) | 2019-05-07 | 2020-11-12 | Precision Biosciences, Inc. | Optimization of engineered meganucleases for recognition sequences |
| US20220251572A1 (en) | 2019-07-23 | 2022-08-11 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| EP4004216A1 (en) | 2019-07-25 | 2022-06-01 | Precision BioSciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| AU2020333851A1 (en) | 2019-08-20 | 2022-03-31 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| EP4069285A1 (en) | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| US20230183664A1 (en) | 2020-05-11 | 2023-06-15 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| CA3190266A1 (en) | 2020-07-30 | 2022-02-03 | Institut Curie | Immune cells defective for socs1 |
| WO2022035793A1 (en) | 2020-08-10 | 2022-02-17 | Precision Biosciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| WO2022165111A1 (en) | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| EP4304632A2 (en) | 2021-03-11 | 2024-01-17 | Mnemo Therapeutics | Tumor neoantigenic peptides |
| WO2022189639A1 (en) | 2021-03-11 | 2022-09-15 | Mnemo Therapeutics | Tumor neoantigenic peptides and uses thereof |
| US20250041412A1 (en) | 2021-03-11 | 2025-02-06 | Institut Curie | Transmembrane neoantigenic peptides |
| AU2022366987A1 (en) | 2021-10-14 | 2024-05-16 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| WO2023064872A1 (en) | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| EP4456910A1 (en) | 2021-12-28 | 2024-11-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| EP4460334A1 (en) | 2022-01-07 | 2024-11-13 | Precision BioSciences, Inc. | Optimized polynucleotides for protein expression |
| US20250115916A1 (en) | 2022-01-21 | 2025-04-10 | Mnemo Therapeutics | Modulation of suv39h1 expression by rnas |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2024059704A1 (en) * | 2022-09-14 | 2024-03-21 | The Johns Hopkins University | Compositions of chimeric autoantigen-t cell receptor (catcr)-t cells and methods of making and using the same |
| WO2024148167A1 (en) | 2023-01-05 | 2024-07-11 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene |
| WO2025076415A1 (en) * | 2023-10-06 | 2025-04-10 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Inducible transgenes encoding intracellular molecules for modulating immune cell function |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025193386A1 (en) | 2024-03-13 | 2025-09-18 | Caribou Biosciences, Inc. | Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells |
| CN118290517B (zh) * | 2024-04-16 | 2024-11-22 | 天津迪丽伟睿生物科技有限公司 | 一种短肽衍生物及其应用、短肽衍生物水凝胶及其应用 |
| WO2026062222A1 (en) | 2024-09-20 | 2026-03-26 | Institut Curie | Novel protein isoforms and uses |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US895828A (en) | 1907-11-08 | 1908-08-11 | J G Brill Co | Sand-box for cars. |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| US20100151556A1 (en) | 2002-03-15 | 2010-06-17 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| CA2891996A1 (en) | 2005-10-18 | 2007-04-26 | Duke University | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| EP2329017A2 (en) | 2008-08-04 | 2011-06-08 | Cellectis | Novel method to generate meganucleases with altered characteristics |
| EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| DK2714936T3 (en) | 2011-06-01 | 2019-03-25 | Prec Biosciences Inc | METHODS AND PRODUCTS FOR PRODUCING MANIPULATED MAMMAL CELL LINES WITH AMPLIFIED TRANSGENES |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| KR20140019635A (ko) | 2012-08-06 | 2014-02-17 | 엘지이노텍 주식회사 | 발광 소자 및 발광 소자 패키지 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| JP6346266B2 (ja) | 2013-03-21 | 2018-06-20 | サンガモ セラピューティクス， インコーポレイテッド | 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊 |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| US11311575B2 (en) * | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| JP6488283B2 (ja) | 2013-05-31 | 2019-03-20 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃ−ｃケモカイン受容体５型（ｃｃｒ５）遺伝子を開裂するｌａｇｌｉｄａｄｇホーミングエンドヌクレアーゼおよびその用途 |
| US10000746B2 (en) | 2013-05-31 | 2018-06-19 | Cellectis | LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof |
| CN105899665B (zh) * | 2013-10-17 | 2019-10-22 | 桑格摩生物科学股份有限公司 | 用于核酸酶介导的基因组工程改造的递送方法和组合物 |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| MX373460B (es) | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| CA2942268A1 (en) | 2014-03-12 | 2015-09-17 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| WO2015167766A1 (en) | 2014-04-29 | 2015-11-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies |
| RS60359B1 (sr) * | 2014-06-06 | 2020-07-31 | Regeneron Pharma | Postupci i kompozicije za modifikovanje ciljanog lokusa |
| CA2959428A1 (en) * | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| WO2016069282A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| KR20260048600A (ko) | 2015-03-27 | 2026-04-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP3322297B1 (en) | 2015-07-13 | 2024-12-04 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| CN117070468A (zh) | 2015-10-05 | 2023-11-17 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| EP3359660B1 (en) | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| WO2017070429A1 (en) | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Methods involving editing polynucleotides that encode t cell receptor |
| EP3988655A3 (en) | 2015-12-23 | 2022-08-03 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| MX2018010924A (es) * | 2016-03-11 | 2019-02-13 | Bluebird Bio Inc | Células efectoras inmunitarias con edición genómica. |
| US11377637B2 (en) * | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| CA3095795A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
-
2016
- 2016-10-05 CN CN202311072847.6A patent/CN117070468A/zh active Pending
- 2016-10-05 KR KR1020187012975A patent/KR20180054886A/ko not_active Ceased
- 2016-10-05 JP JP2018517380A patent/JP6816133B2/ja active Active
- 2016-10-05 EP EP20172471.3A patent/EP3756682B8/en active Active
- 2016-10-05 AU AU2016333898A patent/AU2016333898B2/en active Active
- 2016-10-05 IL IL321898A patent/IL321898A/en unknown
- 2016-10-05 EP EP16782371.5A patent/EP3359184B1/en active Active
- 2016-10-05 DK DK16782371.5T patent/DK3359184T3/da active
- 2016-10-05 MX MX2018004146A patent/MX2018004146A/es unknown
- 2016-10-05 IL IL296340A patent/IL296340A/en unknown
- 2016-10-05 IL IL287319A patent/IL287319B2/en unknown
- 2016-10-05 ES ES20172471T patent/ES2920525T3/es active Active
- 2016-10-05 ES ES16782371T patent/ES2803728T3/es active Active
- 2016-10-05 CA CA3001011A patent/CA3001011A1/en active Pending
- 2016-10-05 DK DK20172471.3T patent/DK3756682T3/da active
- 2016-10-05 EP EP22163286.2A patent/EP4108255A1/en active Pending
- 2016-10-05 WO PCT/US2016/055492 patent/WO2017062451A1/en not_active Ceased
- 2016-10-05 KR KR1020257000732A patent/KR20250013291A/ko active Pending
- 2016-10-05 CN CN201680069576.0A patent/CN108601821B/zh active Active
-
2017
- 2017-05-26 US US15/606,995 patent/US9889160B2/en active Active
- 2017-05-26 US US15/607,059 patent/US9889161B2/en active Active
-
2018
- 2018-01-08 US US15/865,089 patent/US9969975B1/en active Active
- 2018-01-08 US US15/864,947 patent/US9993501B2/en active Active
- 2018-01-08 US US15/864,984 patent/US9950010B1/en active Active
- 2018-01-08 US US15/865,055 patent/US9993502B1/en active Active
- 2018-01-08 US US15/865,075 patent/US9950011B1/en active Active
- 2018-04-04 MX MX2023001878A patent/MX2023001878A/es unknown
- 2018-04-04 IL IL258503A patent/IL258503B/en active IP Right Grant
- 2018-04-27 US US15/964,446 patent/US10093900B2/en active Active
- 2018-04-27 US US15/964,423 patent/US10093899B1/en active Active
- 2018-10-02 US US16/150,179 patent/US20190194616A1/en not_active Abandoned
-
2020
- 2020-12-23 JP JP2020213180A patent/JP2021072785A/ja active Pending
-
2021
- 2021-01-10 IL IL280073A patent/IL280073B/en unknown
- 2021-02-11 AU AU2021200863A patent/AU2021200863A1/en not_active Abandoned
- 2021-03-01 US US17/189,243 patent/US11268065B2/en active Active
-
2022
- 2022-01-19 US US17/579,502 patent/US20220135945A1/en not_active Abandoned
- 2022-01-19 US US17/579,451 patent/US20220145251A1/en not_active Abandoned
- 2022-08-30 JP JP2022136683A patent/JP2022180388A/ja active Pending
-
2023
- 2023-01-17 US US18/155,615 patent/US20240002796A1/en not_active Abandoned
- 2023-04-28 JP JP2023074010A patent/JP2023106422A/ja active Pending
- 2023-12-28 JP JP2023222699A patent/JP2024045153A/ja active Pending
-
2024
- 2024-07-24 AU AU2024205047A patent/AU2024205047A1/en active Pending
-
2025
- 2025-08-08 JP JP2025133019A patent/JP2025179069A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535663A5 (https=) | ||
| JP2018536390A5 (https=) | ||
| US11268065B2 (en) | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene | |
| US20220282285A1 (en) | Genetically-edited immune cells and methods of therapy | |
| JP6929837B2 (ja) | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ | |
| JP2024147602A (ja) | 組換え受容体を発現する細胞の作製方法および関連組成物 | |
| KR20220016475A (ko) | 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법 | |
| KR20230042283A (ko) | 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법 | |
| KR20230157387A (ko) | Cas 효소를 이용한 다중 편집 | |
| HK40087901A (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK40043947A (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK40043947B (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |